Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bodo Levkau

Showing results (1-10 of 150) with videos related to

Pageof 15
Sort By:
Frontiers in Pharmacology|November 6, 2015
HDL-S1P: cardiovascular functions, disease-associated alterations, and therapeutic applicationsBodo Levkau
Handbook of Experimental Pharmacology|April 9, 2013
Cardiovascular effects of sphingosine-1-phosphate (S1P)Bodo Levkau
Journal of Molecular and Cellular Cardiology|October 26, 2010
Survivin signalling in the heartBodo Levkau
Circulation Research|August 2, 2008
Sphingosine-1-phosphate in the regulation of vascular tone: a finely tuned integration system of S1P sources, receptors, and vascular responsivenessBodo Levkau
Basic Research in Cardiology|March 8, 2008
Opportunities, challenges, and caveats of successful molecular imaging of cardiovascular diseasesBodo Levkau
Pharmacology & Therapeutics|June 30, 2023
An erythrocyte-centric view on the MFSD2B sphingosine-1-phosphate transporterShahrooz Ghaderi, Bodo Levkau
Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology|May 27, 2010
Endothelial functions of sphingosine-1-phosphateSusann Lucke, Bodo Levkau
Cardiovascular Research|February 24, 2009
Sphingosine-1-phosphate as a mediator of high-density lipoprotein effects in cardiovascular protectionKatherine Sattler, Bodo Levkau
Heart Failure Reviews|June 8, 2007
HDL and its sphingosine-1-phosphate content in cardioprotectionPetra Keul, Katherine Sattler, Bodo Levkau
Experimental Cell Research|September 24, 2002
ADAM15 is an adherens junction molecule whose surface expression can be driven by VE-cadherinClaire Ham, Bodo Levkau, Elaine W Raines, et al.
Pageof 15

Showing results (1-10 of 150) with videos related to

Sort By:
Pageof 15
Frontiers in Pharmacology|November 6, 2015
HDL-S1P: cardiovascular functions, disease-associated alterations, and therapeutic applicationsBodo Levkau
Handbook of Experimental Pharmacology|April 9, 2013
Cardiovascular effects of sphingosine-1-phosphate (S1P)Bodo Levkau
Journal of Molecular and Cellular Cardiology|October 26, 2010
Survivin signalling in the heartBodo Levkau
Circulation Research|August 2, 2008
Sphingosine-1-phosphate in the regulation of vascular tone: a finely tuned integration system of S1P sources, receptors, and vascular responsivenessBodo Levkau
Basic Research in Cardiology|March 8, 2008
Opportunities, challenges, and caveats of successful molecular imaging of cardiovascular diseasesBodo Levkau
Pharmacology & Therapeutics|June 30, 2023
An erythrocyte-centric view on the MFSD2B sphingosine-1-phosphate transporterShahrooz Ghaderi, Bodo Levkau
Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology|May 27, 2010
Endothelial functions of sphingosine-1-phosphateSusann Lucke, Bodo Levkau
Cardiovascular Research|February 24, 2009
Sphingosine-1-phosphate as a mediator of high-density lipoprotein effects in cardiovascular protectionKatherine Sattler, Bodo Levkau
Heart Failure Reviews|June 8, 2007
HDL and its sphingosine-1-phosphate content in cardioprotectionPetra Keul, Katherine Sattler, Bodo Levkau
Experimental Cell Research|September 24, 2002
ADAM15 is an adherens junction molecule whose surface expression can be driven by VE-cadherinClaire Ham, Bodo Levkau, Elaine W Raines, et al.
Pageof 15